Cargando…

Age and frailty in COVID-19 vaccine development

Detalles Bibliográficos
Autores principales:	Andrew, Melissa K, McElhaney, Janet E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674981/ https://www.ncbi.nlm.nih.gov/pubmed/33220853 http://dx.doi.org/10.1016/S0140-6736(20)32481-8

Ejemplares similares

Considering Frailty in SARS-CoV-2 Vaccine Development: How Geriatricians Can Assist
por: Andrew, Melissa K, et al.
Publicado: (2021)

Immunosenescence Modulation by Vaccination
por: McElhaney, Janet E.
Publicado: (2008)

Immunosenescence Modulation by Vaccination
por: McElhaney, Janet E.
Publicado: (2019)

Frailty Is Associated With Increased Hemagglutination-Inhibition Titers in a 4-Year Randomized Trial Comparing Standard- and High-Dose Influenza Vaccination
por: Loeb, Nathalie, et al.
Publicado: (2020)

Recent advances in influenza vaccines
por: Pawelec, Graham, et al.
Publicado: (2020)

Immunosenescence and Influenza Vaccine Efficacy
por: Sambhara, Suryaprakash, et al.
Publicado: (2009)

Vaccines for Improved Cellular Immunity to Influenza
por: Pawelec, Graham, et al.
Publicado: (2018)

Improving seasonal influenza vaccination for older adults
por: Pawelec, Graham, et al.
Publicado: (2021)

Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
por: Pawelec, Graham, et al.
Publicado: (2021)

Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection
por: Merani, Shahzma, et al.
Publicado: (2017)

Older Age and Frailty are Associated with Higher Mortality but Lower ICU Admission with COVID-19
por: Andrew, Melissa K., et al.
Publicado: (2022)

COVID-19 vaccines in the age of the delta variant
por: Wheatley, Adam K, et al.
Publicado: (2022)

The starting line for COVID-19 vaccine development
por: Lee, Nelson, et al.
Publicado: (2020)

T-Cell Immunity to Influenza in Older Adults: A Pathophysiological Framework for Development of More Effective Vaccines
por: McElhaney, Janet E., et al.
Publicado: (2016)

Influence of Obesity on Pneumococcus Infection Risk in the Elderly
por: Frasca, Daniela, et al.
Publicado: (2019)

Advanced biological age is associated with improved antibody responses in older high-dose influenza vaccine recipients over four consecutive seasons
por: Verschoor, Chris P., et al.
Publicado: (2022)

Developing COVID-19 vaccine policy in increments
por: Saag, Michael S
Publicado: (2021)

COVID-19 vaccination for children aged 5–11 years
por: Ladhani, Shamez N
Publicado: (2022)

Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
por: McElhaney, Janet E., et al.
Publicado: (2011)

Granzyme B: A Double-Edged Sword in the Response to Influenza Infection in Vaccinated Older Adults
por: Verschoor, Chris P., et al.
Publicado: (2021)

Antibody and Cell-Mediated Immune Responses Are Correlates of Protection against Influenza Infection in Vaccinated Older Adults
por: Verschoor, Chris P., et al.
Publicado: (2021)

Vaccine development lessons between HIV and COVID-19
por: Vasan, Sandhya, et al.
Publicado: (2021)

Inclusion of pregnant women in COVID-19 vaccine development
por: Heath, Paul T, et al.
Publicado: (2020)

The Canadian Frailty Priority Setting Partnership: Research Priorities for Older Adults Living with Frailty
por: Bethell, Jennifer, et al.
Publicado: (2019)

Brand inequity in access to COVID-19 vaccines
por: Sheel, Meru, et al.
Publicado: (2022)

Key Determinants of Cell-Mediated Immune Responses: A Randomized Trial of High Dose Vs. Standard Dose Split-Virus Influenza Vaccine in Older Adults
por: Verschoor, Chris P., et al.
Publicado: (2021)

Corrigendum: Key Determinants of Cell-Mediated Immune Responses: A Randomized Trial of High Dose Vs. Standard Dose Split-Virus Influenza Vaccine in Older Adults
por: Verschoor, Chris P., et al.
Publicado: (2021)

COVID-19 vaccine hesitancy
por: Dubé, Eve, et al.
Publicado: (2022)

Mandatory COVID-19 vaccination and human rights
por: King, Jeff, et al.
Publicado: (2022)

Next-generation COVID-19 vaccines: here come the proteins
por: Blakney, Anna K, et al.
Publicado: (2021)

Extending the interval of COVID-19 vaccine regimens in individuals aged 80 years or older
por: Iversen, Patrick L, et al.
Publicado: (2021)

COVID-19 outbreaks in acute and long-term care: Conceptualizing patterns of vulnerability and benefits of interventions
por: Andrew, Melissa K., et al.
Publicado: (2022)

Influenza-Specific T Cells from Older People Are Enriched in the Late Effector Subset and Their Presence Inversely Correlates with Vaccine Response
por: Wagar, Lisa E., et al.
Publicado: (2011)

COVID-19 susceptibility in long-term care facilities
por: Andrew, Melissa K, et al.
Publicado: (2021)

Modelling vaccination strategies for COVID-19
por: Wagner, Caroline E., et al.
Publicado: (2022)

Ensuring global access to COVID-19 vaccines
por: Yamey, Gavin, et al.
Publicado: (2020)

Vaccine Verification in the COVID-19 World
por: Salmon, Daniel A., et al.
Publicado: (2021)

COVID-19 vaccines for the European region: an unprecedented challenge
por: Kluge, Hans, et al.
Publicado: (2021)

Radiation Recall Phenomenon Following COVID-19 Vaccination
por: Stewart, Rachel, et al.
Publicado: (2021)

Incentives for COVID-19 vaccination
por: Brewer, Noel T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o2d8dhp9d6941r5376rr2kr9j7